cyprotex
the ADME Tox specialists
welcome to cyprotex

Investor News

January 29, 2010 - Trading Update and Notice of Results

Cyprotex PLC ('Cyprotex' or 'the Company')

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, announces a trading update on its performance in the calendar year ending 31 December 2009.

Following the Company's announcement on 20 November 2009, the Company confirms a solid level of activity in the months of November and December 2009, and as a result the Directors expect to report full year 2009 results to be in line with market expectations.

Cyprotex expects to report its final year end results to December 2009 on 17 March 2010.

For further information:

Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Noble & Company
John Llewellyn-Lloyd
Sam Reynolds
Tel: +44 (0) 20 7763 2200
sam.reynolds@noblegp.com
www.noblegp.com

Financial Dynamics
Ben Brewerton / Ben Atwell / John Dineen
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 24th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.